a public good project by the
Synthesis
Company
of California

© 2026

Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy | doi.page

0 citations0 references

Google Scholar doi.org

Inhibition of P-glycoprotein function by XR9576 in a solid tumour model can restore anticancer drug efficacy

European Journal of Cancer·2003·Vol. 40(4), pp. 594–605

Citations Over TimeTop 10% of 2003 papers

J Walker, Andrew C.R. Martin, Richard Callaghan

Related Papers

→ Designed P-glycoprotein inhibitors with triazol-tetrahydroisoquinoline-core increase doxorubicin-induced mortality in multidrug resistant K562/A02 cells(2019)27 cited
→ What Kinds of Substrates Show P-Glycoprotein-Dependent Intestinal Absorption? Comparison of Verapamil with Vinblastine(2006)57 cited
→ Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors(1990)70 cited
Ganoderic acid Me improves the sensitivity of multidrug resistant KB-A-1/Dox cells to doxorubicin(2013)
Effects of vinblastine, colchicine, and verapamil on rhodamine 123 accumulation in human P-glycoprotein-positive leukemia cells.(1995)